Ventricular Septal Defect

Ventricular septal defect (VSD) is a congenital cardiac malformation characterized by an abnormal communication between the left and right ventricles. This defect results from incomplete septation of the ventricular chambers during embryonic development, leading to a persistent opening in the interventricular septum. The hemodynamic consequences depend on the size and location of the defect, as well as the relative resistances of the pulmonary and systemic vascular beds. In small defects, the shunt is restrictive, and the volume overload is minimal, often resulting in a benign clinical course. In contrast, large defects are non-restrictive, allowing significant left-to-right shunting, which leads to left ventricular volume overload, pulmonary overcirculation, and potentially pulmonary hypertension. Over time, if untreated, severe pulmonary vascular disease may develop, leading to Eisenmenger physiology with bidirectional or right-to-left shunting and cyanosis. VSD is one of the most common congenital heart defects in dogs and cats, and its clinical presentation ranges from an incidental murmur to severe congestive heart failure in young animals.

The exact etiology of VSD in veterinary patients is often unknown, but it is considered a congenital defect with a multifactorial origin. Genetic predisposition is suspected in certain breeds, such as the English Bulldog, where VSD is frequently diagnosed. In some cases, teratogenic influences during cardiac development, such as maternal infections, nutritional deficiencies, or exposure to certain drugs, may play a role, although specific agents are rarely identified in spontaneous cases. In experimental models, VSD can be induced by various interventions, but in clinical practice, most cases are sporadic. The defect arises from failure of the interventricular septum to fuse completely during embryogenesis, which may involve the membranous or muscular portions of the septum. The membranous septum is the most common site of VSD in dogs and cats, accounting for the majority of cases, while muscular defects are less frequent. The precise molecular mechanisms are not fully understood, but abnormalities in neural crest cell migration, signaling pathways (e.g., bone morphogenetic proteins, Notch), and extracellular matrix remodeling have been implicated in the pathogenesis of septal defects.

VSD is one of the most frequently diagnosed congenital heart defects in dogs and cats. In dogs, it accounts for approximately 15-20% of all congenital cardiac anomalies, making it the second most common defect after patent ductus arteriosus (PDA). Certain breeds are overrepresented, including the English Bulldog, Keeshond, and Alaskan Malamute, suggesting a genetic component. In cats, VSD is also relatively common, though it may be less frequently diagnosed due to subtle clinical signs. The defect is typically identified in young animals, often during routine physical examination when a heart murmur is auscultated. There is no significant sex predilection reported. The prevalence of VSD in the general canine population is estimated to be around 0.1-0.2%, but this may be an underestimate due to subclinical cases. In a large retrospective study of congenital heart disease in dogs, VSD was found in 15.8% of cases, with a higher incidence in purebred dogs compared to mixed breeds. In cats, VSD is often found in conjunction with other cardiac anomalies, such as tetralogy of Fallot, but isolated VSD is also seen.

The pathophysiology of VSD is primarily hemodynamic. During systole, the left ventricular pressure is significantly higher than the right ventricular pressure, driving blood from the left ventricle to the right ventricle through the defect. The magnitude of the left-to-right shunt depends on the size of the defect and the pulmonary-to-systemic vascular resistance ratio. In small, restrictive defects, the shunt is limited, and the volume overload on the left heart is minimal, often resulting in no significant clinical signs. In moderate to large defects, the shunt is substantial, leading to increased pulmonary blood flow, which causes volume overload of the left atrium and left ventricle. This chronic volume overload leads to eccentric hypertrophy of the left ventricle and dilation of the left atrium. The increased pulmonary blood flow also causes pulmonary vascular remodeling, initially with reversible medial hypertrophy and later with irreversible intimal fibrosis and obliterative changes. As pulmonary vascular resistance rises, the shunt may become bidirectional or right-to-left, leading to cyanosis and Eisenmenger physiology. The right ventricle may also become hypertrophied due to increased pulmonary arterial pressure. The clinical consequences include exercise intolerance, respiratory distress, and congestive heart failure. In some cases, the defect may spontaneously close, particularly if it is small and located in the muscular septum, due to growth of surrounding tissue.

Predisposing factors for VSD include genetic susceptibility, breed predisposition, and possibly environmental teratogens. Breeds such as the English Bulldog, Keeshond, and Alaskan Malamute have a higher incidence, suggesting a hereditary component. In the Keeshond, a polygenic mode of inheritance has been proposed. Other factors that may increase the risk of congenital heart defects in general include maternal infections (e.g., parvovirus), nutritional deficiencies (e.g., taurine deficiency in cats), and exposure to certain drugs or toxins during pregnancy, although these are not well-documented for VSD specifically. The presence of other congenital anomalies, such as patent ductus arteriosus or pulmonic stenosis, may also be associated with VSD. Age is a predisposing factor in that clinical signs typically manifest in young animals, but small defects may remain asymptomatic throughout life. Sex does not appear to be a significant risk factor.

Clinical signs of VSD vary widely depending on the size of the defect and the degree of shunting. In animals with small, restrictive defects, there may be no clinical signs, and the only abnormality is a systolic heart murmur, typically loudest at the right heart base or left sternal border. These animals are often asymptomatic and may live a normal lifespan. In animals with moderate to large defects, clinical signs may appear within the first few months of life and include exercise intolerance, tachypnea, respiratory distress, failure to thrive, and stunted growth. In severe cases, signs of congestive heart failure may develop, including coughing, dyspnea, pulmonary crackles, and ascites. If pulmonary hypertension develops and the shunt reverses, cyanosis may be observed, particularly during exercise. Physical examination findings may include a holosystolic murmur, a palpable precordial thrill, and a hyperdynamic apex beat. In cases with significant left-to-right shunting, the femoral pulses may be hyperkinetic. In advanced stages, signs of right-sided heart failure, such as jugular venous distension and hepatomegaly, may be present.

Differential diagnoses for VSD include other congenital heart defects that cause a systolic murmur and left-to-right shunting, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and atrioventricular septal defect (AVSD). PDA typically produces a continuous murmur, whereas VSD produces a holosystolic murmur. ASD may be asymptomatic and has a soft systolic murmur with a fixed split second heart sound. AVSD may have a similar murmur to VSD but is often associated with other abnormalities. Other differentials include pulmonic stenosis, aortic stenosis, and mitral regurgitation, which can also produce systolic murmurs. In young animals, physiologic murmurs are common and may be mistaken for VSD. Diagnostic imaging, particularly echocardiography, is essential to differentiate these conditions. In cases with cyanosis, tetralogy of Fallot, which includes VSD, pulmonic stenosis, right ventricular hypertrophy, and overriding aorta, must be considered. Additionally, acquired conditions such as endocarditis or myocardial disease may cause murmurs, but these are less likely in young animals.

The diagnostic approach to VSD begins with a thorough physical examination, including auscultation and palpation of the precordium. If a systolic murmur is detected, the next step is thoracic radiography to assess cardiac size and pulmonary vasculature. Radiographic findings may include cardiomegaly, particularly left atrial and left ventricular enlargement, and increased pulmonary vascularity. If radiographs are suggestive of a shunt, echocardiography is the gold standard for diagnosis. Two-dimensional echocardiography can directly visualize the defect, while color-flow Doppler can confirm the direction and magnitude of the shunt. Spectral Doppler can estimate the pressure gradient across the defect, which helps assess the severity of the shunt. In cases where pulmonary hypertension is suspected, Doppler-derived pulmonary arterial pressure can be estimated. Electrocardiography may show evidence of left atrial or ventricular enlargement, but it is not specific. In complex cases, cardiac catheterization may be indicated to measure pressures and oxygen saturations, but it is rarely necessary for routine diagnosis. Advanced imaging such as CT or MRI may be used in research or complex cases, but echocardiography remains the primary diagnostic tool.

Laboratory findings in VSD are generally non-specific. Complete blood count may be normal, but in cases of congestive heart failure, there may be a stress leukogram. Serum biochemistry may show mild elevations in liver enzymes due to hepatic congestion in right-sided heart failure. In cases with cyanosis, polycythemia may be present due to chronic hypoxia. Arterial blood gas analysis may reveal hypoxemia in cases with right-to-left shunting. Biomarkers such as NT-proBNP may be elevated in animals with heart failure, but they are not specific for VSD. In cases with pulmonary hypertension, there may be evidence of right heart strain on electrocardiography, but this is not a laboratory finding. Urinalysis is typically unremarkable. In general, laboratory tests are used to assess the severity of heart failure and to rule out other causes of the clinical signs, but they do not confirm the diagnosis of VSD.

Thoracic radiography is the initial imaging modality. In small VSDs, radiographs may be normal. In larger defects, findings include generalized cardiomegaly, with left atrial and left ventricular enlargement, and increased pulmonary vascularity due to overcirculation. The main pulmonary artery segment may be prominent. In cases with pulmonary hypertension, there may be evidence of right ventricular enlargement and pruning of the peripheral pulmonary vasculature. Echocardiography is the definitive imaging tool. Two-dimensional echocardiography can visualize the defect in the interventricular septum, typically in the membranous or muscular region. Color-flow Doppler demonstrates turbulent flow across the defect, and spectral Doppler can measure the velocity of the shunt, which allows estimation of the pressure gradient between the ventricles. In cases with pulmonary hypertension, the shunt velocity may be low, and the direction may be bidirectional or right-to-left. Echocardiography also assesses the degree of cardiac chamber enlargement and ventricular function. In some cases, transesophageal echocardiography may be used for better visualization, but it is rarely necessary in veterinary patients. Advanced imaging such as CT or MRI is not routinely used but may be helpful in complex cases or for surgical planning.

Cytology and histopathology are not typically used in the diagnosis of VSD, as the diagnosis is made by imaging. However, if a biopsy of the myocardium is obtained during surgery or postmortem, histopathological findings may include hypertrophy of the ventricular myocardium, particularly the left ventricle, and dilation of the cardiac chambers. In cases with pulmonary hypertension, there may be medial hypertrophy of the pulmonary arterioles and intimal fibrosis. These changes are non-specific and reflect the hemodynamic consequences of the defect. In cases of infective endocarditis, which can be a complication of VSD, histopathology may show vegetative lesions on the endocardium, particularly on the right ventricular side of the defect. Cytology of pericardial or pleural fluid may be performed if effusion is present, but it is not diagnostic for VSD.

Treatment of VSD depends on the severity of the defect and the presence of clinical signs. For small, asymptomatic defects, no treatment is required, and the animal can be monitored periodically. For moderate to large defects with clinical signs, medical management may be initiated to control congestive heart failure. This includes the use of diuretics such as furosemide (2-4 mg/kg IV, IM, SC, or PO q8-12h), ACE inhibitors such as enalapril (0.5 mg/kg PO q12-24h) or benazepril (0.25-0.5 mg/kg PO q24h), and positive inotropes such as pimobendan (0.25-0.3 mg/kg PO q12h) in cases of systolic dysfunction. In cases with pulmonary hypertension, sildenafil (1-2 mg/kg PO q8-12h) may be used to reduce pulmonary arterial pressure. Surgical closure of the defect is the definitive treatment and is recommended for animals with large defects that are refractory to medical management. Surgical options include patch closure using cardiopulmonary bypass, which is technically challenging and requires specialized equipment, or transcatheter closure using an occluder device, which is less invasive and has been performed successfully in some cases. However, these procedures are not widely available and carry significant risks. In cases with severe pulmonary hypertension and right-to-left shunting, surgical closure is contraindicated due to the risk of right heart failure. In such cases, treatment is palliative, focusing on managing the pulmonary hypertension and preventing complications such as polycythemia.

The prognosis for VSD is highly variable and depends on the size of the defect and the presence of clinical signs. Animals with small, restrictive defects have an excellent prognosis and may live a normal lifespan without any treatment. Animals with moderate defects may develop clinical signs later in life, but with appropriate medical management, they can have a good quality of life for several years. Animals with large defects that develop congestive heart failure or pulmonary hypertension have a guarded to poor prognosis, especially if the defect is not corrected. The development of Eisenmenger physiology carries a poor prognosis, with a median survival time of less than 1-2 years after the onset of cyanosis. Surgical closure can improve the prognosis in selected cases, with reported survival rates of over 90% in animals that survive the perioperative period. However, the availability of surgical expertise and the cost of the procedure are limiting factors. Overall, the prognosis is better for animals with small defects and those that respond well to medical therapy.

Follow-up for animals with VSD depends on the severity of the defect. For asymptomatic animals with small defects, re-evaluation every 6-12 months is recommended to monitor for any changes in the murmur or the development of clinical signs. For animals with moderate to large defects receiving medical therapy, more frequent re-checks are necessary, initially every 1-3 months until the condition is stable, then every 3-6 months. Monitoring should include physical examination, thoracic radiography, and echocardiography to assess the size of the defect, the degree of shunting, and the progression of cardiac remodeling. In animals with pulmonary hypertension, serial Doppler echocardiography to estimate pulmonary arterial pressure is important. Blood tests, including NT-proBNP, may be useful to monitor the severity of heart failure. In animals that have undergone surgical closure, follow-up echocardiography is recommended at 1, 3, 6, and 12 months postoperatively, and then annually, to ensure the defect is completely closed and to monitor for any residual shunting or complications.

Pearls: 1. A loud, holosystolic murmur at the right heart base or left sternal border in a young animal is highly suggestive of VSD. 2. Echocardiography with color-flow Doppler is essential for confirming the diagnosis and assessing the severity of the shunt. 3. Small VSDs may close spontaneously, so a conservative approach with regular monitoring is appropriate. 4. In cases with pulmonary hypertension, the murmur may become softer or disappear, and the shunt may become right-to-left, leading to cyanosis. 5. Surgical closure is the only definitive treatment, but it is not always feasible; medical management can improve quality of life. Pitfalls: 1. Failing to recognize that a VSD can be associated with other congenital defects, such as pulmonic stenosis or aortic stenosis, which may alter the clinical presentation. 2. Misinterpreting a physiologic murmur as a VSD, leading to unnecessary anxiety and testing. 3. Overlooking the possibility of infective endocarditis in animals with VSD, especially if they have a fever or new murmur. 4. In cases with large defects, delaying referral to a specialist may lead to irreversible pulmonary vascular disease. 5. Using diuretics excessively in animals with VSD can cause dehydration and worsen renal function, especially in those with right-to-left shunting.

For congestive heart failure secondary to VSD: Furosemide: 2-4 mg/kg IV, IM, SC, or PO q8-12h; adjust dose based on clinical response and renal function. Enalapril: 0.5 mg/kg PO q12-24h; start at lower dose and titrate up. Benazepril: 0.25-0.5 mg/kg PO q24h. Pimobendan: 0.25-0.3 mg/kg PO q12h; indicated for systolic dysfunction. Spironolactone: 1-2 mg/kg PO q12-24h; may be added as an adjunct diuretic. For pulmonary hypertension: Sildenafil: 1-2 mg/kg PO q8-12h; start at lower dose and titrate to effect. For prophylaxis of infective endocarditis: Amoxicillin: 20 mg/kg PO 1 hour before dental or surgical procedures; or Clindamycin: 11 mg/kg PO 1 hour before procedure in penicillin-allergic animals. For management of polycythemia in right-to-left shunting: Phlebotomy: remove 10-20 ml/kg of blood, and replace with crystalloids; repeat as needed to maintain PCV below 65%. Hydroxyurea: 50 mg/kg PO q48h; use if phlebotomy is insufficient. All dosages are based on Plumb's Veterinary Drug Handbook and should be adjusted based on individual patient needs and renal/hepatic function.

Ventricular septal defect is well-documented in veterinary literature. A retrospective study by Buchanan (1999) reported that VSD accounts for 15.8% of congenital heart defects in dogs, with a higher prevalence in English Bulldogs. Echocardiographic features and natural history have been described in several case series. In a study by Oyama et al. (2001), the clinical outcome of dogs with VSD was evaluated, showing that small defects have a good prognosis, while large defects often lead to heart failure. Surgical closure using cardiopulmonary bypass has been reported in dogs, with successful outcomes in selected cases (e.g., Orton et al., 2001). Transcatheter closure using Amplatzer devices has been described in dogs and cats, with promising results (e.g., Gordon et al., 2009). Medical management with ACE inhibitors and diuretics is standard for heart failure, and sildenafil has been shown to improve exercise tolerance in dogs with pulmonary hypertension (e.g., Bach et al., 2006). ACVIM consensus statements on the diagnosis and treatment of canine heart disease provide guidelines for the management of congenital heart defects, including VSD. Overall, the evidence supports a tailored approach based on the severity of the defect and the presence of clinical signs.